<DOC>
	<DOC>NCT01041807</DOC>
	<brief_summary>This survey is conducted for preparing application material for re-examination under the Pharmaceutical Affairs Law and its Enforcement Regulation; its aim is to reconfirm the clinical usefulness of COZAAR XQ through collecting the safety and efficacy information according to the Re-examination Regulation for New Drugs.</brief_summary>
	<brief_title>Cozaar XQ Re-examination Study (MK-0954-349)</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Inclusion criteria: Participant with essential hypertension Participant who is treated with COZAAR XQ within local label for the first time Exclusion criteria: Participant who is treated with COZAAR XQ before contract and out of enrollment period Participant who has a contraindication to COZAAR XQ according to the local label</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Hypertension</keyword>
</DOC>